Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GYS1 | P13807 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072594 | 1.00 | HRH3 (0.58) | HRH3CYP2C19ALDH1A1DNMT1L3MBTL1 | |
| SCHEMBL4457014 | 0.83 | HRH3 (0.52) | HRH3CYP2C19ALDH1A1DNMT1L3MBTL1 | |
| SCHEMBL4451971 | 0.83 | HRH3 (0.57) | HRH3CYP2C19ALDH1A1DNMT1SMN1; SMN2 | |
| SCHEMBL13837136 | 0.81 | CYP2C19 (0.69) | CYP2C19ALDH1A1DNMT1L3MBTL1SMN1; SMN2 | |
| SCHEMBL12480383 | 0.81 | CYP2C19 (0.69) | CYP2C19ALDH1A1DNMT1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9660764 | 0.78 | HRH3 (0.64) | HRH3CYP2C19ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2003499 | 0.77 | MAPT (0.68) | HRH3CYP2C19ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5742971 | 0.74 | CYP2C19 (0.65) | CYP2C19ALDH1A1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL5742979 | 0.74 | CYP2C19 (0.65) | CYP2C19ALDH1A1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL9418839 | 0.72 | HRH3 (0.67) | HRH3CYP2C19ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | INOUE JUN (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1224945-A1 | TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-1112749-A2 | PREVENTIVES OR REMEDIES FOR EYE CIRCULATORY FAILURE | Senju Pharmaceutical Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | CMA1, THOP1, TPSAB1 | HRH3 804/4885CYP2C19 1360/4885ALDH1A1 1567/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | HRH3 85/4885CYP2C19 736/4885ALDH1A1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.